Free Trial

Sol-Gel Technologies Q1 2024 Earnings Report

Sol-Gel Technologies logo
$0.43 -0.01 (-2.54%)
(As of 12/20/2024 05:16 PM ET)

Sol-Gel Technologies EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.15
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Sol-Gel Technologies Revenue Results

Actual Revenue
$0.47 million
Expected Revenue
$1.30 million
Beat/Miss
Missed by -$830.00 thousand
YoY Revenue Growth
N/A

Sol-Gel Technologies Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

Click here for the ticker >>>

Sol-Gel Technologies Earnings Headlines

Sol-Gel Technologies Reports Strong Q3 2024 Results
Sol-Gel announces 180-day extension to regain compliance with Nasdaq
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment
This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.
See More Sol-Gel Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sol-Gel Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sol-Gel Technologies and other key companies, straight to your email.

About Sol-Gel Technologies

Sol-Gel Technologies (NASDAQ:SLGL), together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

View Sol-Gel Technologies Profile

More Earnings Resources from MarketBeat

Upcoming Earnings